Evidence map›Paper›PMID 25679121›Full record

ArticleJournal of clinical psychopharmacology2015

A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia.

Michael P Caligiuri, Hans-Leo Teulings, Charles E Dean, James B Lohr

Abstract read
In one paragraph

Article in Journal of clinical psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael P CaligiuriFrom the *University of California, San Diego, CA; †NeuroScript LLC, Tempe, AZ; ‡Minneapolis VA, Minneapolis, MN; and §VA Center of Excellence for Stress and Mental Health, San Diego, CA.
Hans-Leo Teulings
Charles E Dean
James B Lohr

Funding

Movement Analysis to Monitor Medication Side EffectsR44MH073192 · NIMH · NEUROSCRIPT, LLC · PI TEULINGS, HANS-LEO · 2006 to 2007
$751k
NIMH NIH HHS R44 MH073192
6 · The paper itself

Abstract

Tardive dyskinesia (TD) is a movement disorder commonly associated with chronic exposure to antidopaminergic medications, which may be in some cases disfiguring and socially disabling. The consensus from a growing body of research on the incidence and prevalence of TD in the modern era of antipsychotics indicates that this disorder has not disappeared continues to challenge the effective management of psychotic symptoms in patients with schizophrenia. A fundamental component in an effective strategy for managing TD is its reliable and accurate assessment. In the present study, we examined the clinical utility of a brief handwriting dysfluency measure for quantifying TD. Digitized samples of handwritten circles and loops were obtained from 62 psychosis patients with or without TD and from 50 healthy subjects. Two measures of dysfluent pen movements were extracted from each vertical pen stroke, including normalized jerk and the number of acceleration peaks. Tardive dyskinesia patients exhibited significantly higher dysfluency scores than non-TD patients and controls. Severity of handwriting movement dysfluency was correlated with Abnormal Involuntary Movement Scale severity ratings for some tasks. The procedure yielded high degrees of test-retest reliability. These results suggest that measures of handwriting movement dysfluency may be particularly useful for objectively evaluating the efficacy of pharmacotherapeutic strategies for treating TD.

Indexed as

HandwritingNeuropsychological TestsAdultAntipsychotic AgentsBiomechanical PhenomenaDiagnosis, DifferentialFemaleHumansMaleMiddle AgedMovement DisordersPsychotic DisordersReproducibility of ResultsSchizophreniaUpper ExtremityAntipsychotic Agents

Identifiers

PMID25679121
PMCPMC4344392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.